Navigation Links
Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment
Date:11/3/2011

and completion of clinical trials and submissions to the FDA or foreign authorities; the volatility and liquidity of the financial markets; our liquidity and capital resources; and our expected future revenues, operations and expenditures. As with any pharmaceutical in development, there are significant risks in the development, the regulatory approval, and commercialization of new products. There are no guarantees that our response to the FDA's CRL or the results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy and subsequent meetings and communications will be sufficient to satisfy the FDA's safety concerns, that the FDA will not require us to conduct any additional prospective studies or retrospective observational studies, or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ending December 31, 2010, and periodic reports filed with the Securities and Exchange Commission.

CONTACT: VIVUS, Inc. Media Relations:GolinHarris Timothy E. MorrisSusan Brophy Chief Financial Officersbrophy@golinharris.com 650-934-5200312-729-4359Investor Relations:The Trout GroupBrian Korbbkorb@troutgroup.com646-378-2923
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Multiple Presentations Featuring QNEXA® Data to be Presented at the European Congress on Obesity
2. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
3. Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits
4. Long-Term Data on QNEXA® to be Presented at The American College of Cardiology Annual Meeting
5. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
6. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
7. New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years
8. Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes
9. Pharmasset Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977 for HCV
10. Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling
11. Cytogel Pharma, LLC. Announces Presentation at the American Society of Anesthesiologists meeting in Chicago on October 18, 2011, Describing Results From its First Human Study, Part of the Phase I Program for Cyt-1010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)...  Vermillion, Inc. (NASDAQ: VRML ), a ... health, has appointed Holly B. Bauzon as ... Ms. Bauzon has a proven track record in both ... services companies. She has more than 20 years of ... held the position of Director, Lab Services Sales and ...
(Date:8/21/2014)... YORK , Aug. 21, 2014  Publicis Groupe ... Shannon Hartley , Managing Partner and Healthcare Industry Group ... PharmaVoice 100, which recognizes the most inspiring people in ... are leaders in research and development, marketing, technology, creativity, ... agency in 2006 as a partner in its leading ...
(Date:8/21/2014)... 2014 /PRNewswire-iReach/ -- Inc. magazine today ... third straight year, No. 349 in Health on ... of the nation,s fastest-growing private companies. The list ... important segment of the economy—America,s independent entrepreneurs. Companies ... LinkedIn, Zillow, and many other well-known names gained ...
Breaking Medicine Technology:Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2Shannon Hartley Shines in PharmaVOICE 100 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3
... 2, 2010 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... Agency (MHRA) in the UK has completed review of the ... acceptance for BMN 673 for genetically-defined cancers.  The company expects ... of 2011. "BMN 673 has been proven to ...
... THOUSAND OAKS, Calif., Dec. 2, 2010 Amgen (Nasdaq: ... from several key Nplate® (romiplostim) studies at the 52nd Annual ... Dec. 4-7, 2010, in Orlando, Fla. Results from six studies ... purpura (ITP) add to the growing body of data supporting ...
Cached Medicine Technology:MHRA Completes Review of CTA and Issues Notice of Acceptance for BMN 673 for Genetically-Defined Cancers 2MHRA Completes Review of CTA and Issues Notice of Acceptance for BMN 673 for Genetically-Defined Cancers 3Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting 2Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting 3Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting 4Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting 5Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting 6Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting 7Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting 8Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting 9Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting 10Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting 11Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting 12Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting 13Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting 14Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting 15
(Date:8/22/2014)... 2014 The regional economy is about ... is on the grow again. The plant will ... 2016 to boost production of the popular Highlander midsize ... overall investment to $4 billion. This step allows Toyota ... additional flexibility to adjust its product mix to meet ...
(Date:8/22/2014)... Americans know little about how Ebola is transmitted and harbor ... United States, a new survey shows. About four in ... a major Ebola outbreak in the United States, and one-quarter ... get sick with the deadly virus in the next year, ... However, those opinions don,t match reality, the Harvard researchers ...
(Date:8/22/2014)... Las Vegas, NV (PRWEB) August 22, 2014 ... that teaches readers how they can use natural methods ... for years has caught the attention of Shane Michaels, ... only a condition that affects the skin, it can ... suffer from it,” reports Michaels. “The intense itching and ...
(Date:8/22/2014)... Epidermal growth factor receptor (EGFR) mutations found in ... of advanced non-small cell lung cancer (NSCLC) patients correlates ... DNA. , EGFR tyrosine kinase inhibitor (TKI) therapy is ... NSCLC, but the standard for determining mutation status is ... be limited or not available. A more abundant and ...
(Date:8/22/2014)... August 22, 2014 Advancements in ... some clinical applications due to their cost-effectiveness, non-invasiveness, ... innovations in ultrasound, such as the evolution of ... to keep the market moving throughout 2014 and ... can enhance not only the point-of-care (POC) testing ...
Breaking Medicine News(10 mins):Health News:Toyota Indiana Adding 300 Jobs to Build More Highlanders 2Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2Health News:Beat Eczema: Review Exposes Susan Clark’s Guide to Curing Eczema Naturally 2Health News:High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 3
... FAIRFAX, Va., Sept. 18 The American Society,for Therapeutic ... growing staff; Barbara Muth is ASTRO,s new director of ... policy analyst., Ms. Muth brings nearly 20 years ... she worked with the American Red Cross for,eight years ...
... HOUSTON, Sept. 18 Today US Oncology, Inc., ... network,announced the appointment of Michael A. Sicuro as ... position Sicuro will lead and manage,the finance function ... financial,analytical, operational, and transactional issues, including accounting,financial reporting, ...
... claim that internationally adopted children can undergo puberty at ... variety of health risks as adults: abdominal obesity, hypertension, ... are internationally adopted children really more at risk? , ... their living conditions up until their adoption," says Hlne ...
... complication of severe burns. Injury to GI function, ... initiator as well as a stimulator for occurrence ... organ dysfunction syndrome following severe burns. With the ... the stereotype of clinical treatment in recent 30 ...
... present brief clinical report showed that Contrast-enhanced ... agent, Sonazoid, can allow surgeons to investigate ... to find new metastases intraoperatively. , ,Contrast-enhanced ... conventional IOUS to identify new occult lesions ...
... an essential role in filling the gap of transplants ... Considering that living related donors are healthy individuals at ... return to quality of life. , A research article ... World Journal of Gastroenterology addresses this question. ...
Cached Medicine News:Health News:ASTRO Names New Research Director, Health Policy Analyst 2Health News:US Oncology Appoints Michael A. Sicuro Executive Vice President and Chief Financial Officer 2Health News:Strategies for preventing gastrointestinal complications in severely burned patients 2Health News:An analysis of the surgical and perioperative complications in right hepatectomies 2
Used to introduce large devices for vascular intervention....
Used for the introduction of catheters, balloons and other vascular devices....
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Sheath Introducer featuring patented SLIX Valve, rotating collar, kink-resistant cannula and atraumatic tip transitions....
Medicine Products: